Prostatic Neoplasms: all 6,484 studies

Page 25 of 65. Open to participants first (1,413), then studies with results posted, then the rest; newest registration first within each.

• Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate CancerCompletedNCT00450463Phase 2Results posted
• Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation TherapyCompletedNCT00450411Phase 2Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate CancerCompletedNCT00439270Phase 1/2Results posted
• Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing SurgeryCompletedNCT00438464Phase 2Results posted
• AZD2171 to Treat Prostate CancerCompletedNCT00436956Phase 2Results posted
• S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00433446Phase 2Results posted
• Testing the Helpfulness of 2 Decision Aids for Prostate CancerCompletedNCT00432601Not applicableResults posted
• Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate CancerActive, not recruitingNCT00430183Phase 3Results posted
• Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and ChemotherapyCompletedNCT00428714Phase 2Results posted
• Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate CancerCompletedNCT00427999Phase 2Results posted
• PS-341 Followed by Removal of Prostate for Those With Prostate CancerCompletedNCT00425503Phase 2Results posted
• Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)CompletedNCT00424385Phase 1Results posted
• Quinacrine Treatment in Patients With Androgen-Independent Prostate CancerCompletedNCT00417274Phase 2Results posted
• XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate CancerCompletedNCT00417079Phase 3Results posted
• Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate CancerCompletedNCT00414388Phase 1/2Results posted
• Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate CancerCompletedNCT00402285Not applicableResults posted
• GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate CancerCompletedNCT00400517Phase 2Results posted
• Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone MetastasesCompletedNCT00390468Phase 2Results posted
• External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate CancerTerminatedNCT00388804Phase 3Results posted
• A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)TerminatedNCT00385827Phase 2Results posted
• Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate CancerCompletedNCT00385580Phase 2Results posted
• Vidaza to Restore Hormone Thx ProstateCompletedNCT00384839Phase 2Results posted
• Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate BrachytherapyCompletedNCT00381966Not applicableResults posted
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results posted
• Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain MetastasesCompletedNCT00377156Phase 3Results posted
• Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast CancerCompletedNCT00365105Phase 3Results posted
• Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In MenCompletedNCT00363311Phase 4Results posted
• Soy Protein/Effexor Hormone Therapy for Prostate CancerTerminatedNCT00354432Phase 3Results posted
• Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate CancerTerminatedNCT00348816Phase 2Results posted
• Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate CancerCompletedNCT00348595Phase 1/2Results posted
• Dendritic Cell Vaccine Study (DC/PC3) for Prostate CancerCompletedNCT00345293Phase 1/2Results posted
• Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00337077Phase 2Results posted
• Radiation Therapy in Treating Patients With Stage II Prostate CancerCompletedNCT00331773Phase 3Results posted
• Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and ChemotherapyCompletedNCT00331344Phase 1/2Results posted
• Vorinostat in Treating Patients With Progressive Metastatic Prostate CancerCompletedNCT00330161Phase 2Results posted
• Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone TherapyCompletedNCT00329797Phase 3Results posted
• Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate CancerCompletedNCT00328614Phase 1Results posted
• Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCCompletedNCT00327340Phase 2Results posted
• Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00323882Phase 1/2Results posted
• Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate CancerTerminatedNCT00321698Phase 1/2Results posted
• Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical ProstatectomyCompletedNCT00321646Phase 2Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerCompletedNCT00321620Phase 3Results posted
• Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)CompletedNCT00313781Phase 2Results posted
• Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate CancerCompletedNCT00311623Phase 1/2Results posted
• Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)CompletedNCT00307294Phase 2Results posted
• Study of SU11248 in Men With Advanced Prostate CancerCompletedNCT00299741Phase 2Results posted
• Maximal Suppression of the Androgen Axis in Clinically Localized Prostate CancerCompletedNCT00298155Phase 2Results posted
• The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate CancerCompletedNCT00295750Phase 3Results posted
• Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate CancerCompletedNCT00292045Phase 1Results posted
• Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.CompletedNCT00289341Phase 1/2Results posted
• Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate CancerCompletedNCT00288080Phase 3Results posted
• Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate CancerCompletedNCT00286091Phase 3Results posted
• Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate CancerCompletedNCT00283803Phase 2Results posted
• Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical ProstatectomyCompletedNCT00283062Phase 3Results posted
• Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior ChemotherapyCompletedNCT00278993Phase 2Results posted
• Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate CancerCompletedNCT00276549Phase 2Results posted
• GM-CSF for Maintenance of Prostate Cancer for Patients Responding to TaxotereCompletedNCT00274287Phase 2Results posted
• Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate CancerCompletedNCT00272038Phase 2Results posted
• Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate CancerCompletedNCT00268892Phase 2/3Results posted
• Role of Soy Supplementation in Prostate Cancer DevelopmentCompletedNCT00255125Phase 3Results posted
• Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate CancerCompletedNCT00253643Not applicableResults posted
• A Study of Imatinib and Docetaxel in Prostate CancerCompletedNCT00251225Phase 2Results posted
• Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00246753Phase 2Results posted
• Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression TherapyCompletedNCT00245518Phase 4Results posted
• Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer PatientsTerminatedNCT00245466Phase 2Results posted
• Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate CancerCompletedNCT00242567Phase 3Results posted
• Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate CancerCompletedNCT00225420Phase 1/2Results posted
• Effects of IAS in Men With Localized Biochemical Relapsed Prostate CancerCompletedNCT00223665Phase 2Results posted
• Fulvestrant in Treating Patients With Recurrent Prostate CancerTerminatedNCT00217464Phase 2Results posted
• Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate CancerCompletedNCT00216099Phase 2Results posted
• Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal TherapyTerminatedNCT00216060Phase 3Results posted
• An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate CancerCompletedNCT00215683Phase 2/3Results posted
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsTerminatedNCT00215657Phase 2Results posted
• Intensity Modulated Radiation Therapy for Prostate CancerCompletedNCT00214422Early Phase 1Results posted
• Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic NodesCompletedNCT00214136Phase 2Results posted
• Phase I/II Hypofractionated Radiotherapy for Prostate CancerCompletedNCT00214097Phase 1/2Results posted
• Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer ScreeningCompletedNCT00207636Not applicableResults posted
• Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus ErlotinibCompletedNCT00203424Phase 2Results posted
• Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate CancerCompletedNCT00195039Phase 2Results posted
• Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate CancerTerminatedNCT00183937Phase 2Results posted
• Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate CancerTerminatedNCT00176644Phase 2Results posted
• Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedNCT00176631Phase 2Results posted
• Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate CancerCompletedNCT00176605Phase 2Results posted
• Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate CancerCompletedNCT00170157Phase 2Results posted
• A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle ContrastTerminatedNCT00147238Not applicableResults posted
• ET 743 (Yondelis) in Men With Advanced Prostate CancerCompletedNCT00147212Phase 2Results posted
• Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate CancerCompletedNCT00142506Phase 3Results posted
• Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate CancerCompletedNCT00137436Phase 1/2Results posted
• S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapyCompletedNCT00134056Phase 3Results posted
• Chemotherapy After Prostatectomy (CAP) For High Risk Prostate CarcinomaCompletedNCT00132301Phase 3Results posted
• Phase I Study of Intensity Modulated Radiation Therapy for Prostate CancerTerminatedNCT00124917Phase 1Results posted
• Cilengitide in Treating Patients With Prostate CancerCompletedNCT00121238Phase 2Results posted
• 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedNCT00118092Phase 2Results posted
• Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486CompletedNCT00117949Phase 2Results posted
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsTerminatedNCT00117312Phase 2Results posted
• Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerCompletedNCT00117286Phase 2/3Results posted
• A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate CancerCompletedNCT00116779Phase 2Results posted
• A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate CancerCompletedNCT00116753Phase 2Results posted
• Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate CancerCompletedNCT00116142Phase 3Results posted

← Prostatic Neoplasms overview